Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.92 Million USD | -333.27% |
| 2022 | -6.07 Million USD | 117.56% |
| 2021 | -9.7 Million USD | -15.59% |
| 2020 | -8.34 Million USD | 5.05% |
| 2019 | -9.99 Million USD | -49.17% |
| 2018 | -7.46 Million USD | -13.28% |
| 2017 | -5.16 Million USD | -41.99% |
| 2016 | -4.58 Million USD | 53.24% |
| 2015 | -8.03 Million USD | -1067.7% |
| 2014 | -665.92 Thousand USD | 19.55% |
| 2013 | -827.76 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.36 Million USD | 2.17% |
| 2024 Q1 | -1.01 Million USD | -102.7% |
| 2023 Q3 | -1.81 Million USD | -141.7% |
| 2023 FY | - USD | -333.27% |
| 2023 Q1 | -3.35 Million USD | -149.82% |
| 2023 Q2 | -752.51 Thousand USD | 77.59% |
| 2023 Q4 | -687.3 Thousand USD | 62.21% |
| 2022 Q2 | -1.39 Million USD | 38.15% |
| 2022 Q1 | -2.25 Million USD | 3.76% |
| 2022 FY | - USD | 117.56% |
| 2022 Q4 | 6.73 Million USD | 578.42% |
| 2022 Q3 | -1.4 Million USD | -1.02% |
| 2021 FY | - USD | -15.59% |
| 2021 Q2 | -2.27 Million USD | 12.8% |
| 2021 Q1 | -2.61 Million USD | 20.82% |
| 2021 Q3 | -2.34 Million USD | -3.02% |
| 2021 Q4 | -2.34 Million USD | 0.11% |
| 2020 Q1 | -2.27 Million USD | -3.38% |
| 2020 Q3 | -2.09 Million USD | -240.5% |
| 2020 Q4 | -3.29 Million USD | -57.32% |
| 2020 FY | - USD | 5.05% |
| 2020 Q2 | -615.42 Thousand USD | 72.95% |
| 2019 Q2 | -2.94 Million USD | -171.68% |
| 2019 Q3 | -2.3 Million USD | 21.55% |
| 2019 Q4 | -2.2 Million USD | 4.65% |
| 2019 FY | - USD | -49.17% |
| 2019 Q1 | -1.08 Million USD | 15.62% |
| 2018 Q4 | -1.28 Million USD | -20.37% |
| 2018 Q3 | -1.06 Million USD | 13.98% |
| 2018 Q2 | -1.23 Million USD | 45.15% |
| 2018 Q1 | -2.25 Million USD | -6.47% |
| 2018 FY | - USD | -13.28% |
| 2017 FY | - USD | -41.99% |
| 2017 Q4 | -2.12 Million USD | -35.57% |
| 2017 Q3 | -1.56 Million USD | -86.81% |
| 2017 Q2 | -837.95 Thousand USD | -31.54% |
| 2017 Q1 | -637.03 Thousand USD | 68.94% |
| 2016 Q1 | -714.32 Thousand USD | 33.56% |
| 2016 FY | - USD | 53.24% |
| 2016 Q4 | -2.05 Million USD | -145.46% |
| 2016 Q3 | -835.55 Thousand USD | 14.99% |
| 2016 Q2 | -982.85 Thousand USD | -37.59% |
| 2015 FY | - USD | -1067.7% |
| 2015 Q3 | -1.98 Million USD | -31.66% |
| 2015 Q2 | -1.5 Million USD | 0.0% |
| 2015 Q1 | -1.5 Million USD | -785.76% |
| 2015 Q4 | -1.07 Million USD | 45.85% |
| 2014 Q4 | -170.24 Thousand USD | 0.0% |
| 2014 FY | - USD | 19.55% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bright Green Corporation | - USD | Infinity% |
| BioQuest Corp. | -33.57 USD | -11684004.856% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 76.658% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 105.061% |
| GSRX Industries Inc. | - USD | Infinity% |
| High Sierra Technologies, Inc. | -181.97 Thousand USD | -2055.483% |
| Instadose Pharma Corp. | - USD | Infinity% |